• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Microbial Composition and Stool Short Chain Fatty Acid Levels in Fibromyalgia (Kim, Kim, Kang, 2023)

Messages
600
Abstract

Background: The present study aimed to evaluate microbial diversity, taxonomic profiles, and fecal short chain fatty acid (SCFA) in female patients with fibromyalgia syndrome (FMS). Methods: Forty participants (19 patients with FMS and 21 controls) were included in the study, and the diagnosis of FMS was made based on the revised American College of Rheumatology criteria. DNA extraction from fecal samples and 16S rRNA gene sequencing were conducted to estimate microbial composition. To compare alpha diversity, the Shannon index accounting for both evenness and richness, Pielou’s evenness, and Faith’s phylogenetic diversity (PD) were calculated. Unweighted and weighted UniFrac distances, Jaccard distance, and Bray–Curtis dissimilarity were used to calculate beta diversity. Furthermore, stool metabolites were analyzed using gas chromatography-mass spectrometry, and a generalized regression model was used to compare the SCFA of stools between FMS and healthy controls. Results: Compared with the control, patients with FMS had lower observed OTU (p = 0.048), Shannon’s index (p = 0.044), and evenness (p < 0.001). Although patients with FMS had a lower PD than did controls, statistical significance was not reached. We observed significant differences in unweighted (p = 0.007), weighted UniFrac-based diversity (p < 0.005), Jaccard distance (p < 0.001), and Bray–Curtis dissimilarity (p < 0.001) between the two groups. Although the FMS groups showed lower propionate levels compared with those of the control group, only marginal significance was observed (0.82 [0.051] mg/g in FMS vs. 1.16 [0.077] mg/g in the control group, p = 0.069). Conclusions: The diversity of the microbiome in the FMS group was lower than that in the control group, and the reduced stool propionate levels could be associated with the decreased abundance of propionate-producing bacteria.

https://www.mdpi.com/1660-4601/20/4/3183
 

LINE

Senior Member
Messages
861
Location
USA
Good article, thanks for posting. I am not sure if anyone has read the latest report(s) that were released this last week about the microbiome studies done on CFS/ME vs Normal controls. The data suggests that essential microbes are missing out of the CFS group - these microbes are SCFA producers. The propionate is one of the SCFA (short chain fatty acids) along with butyrate. These SCFAs help curb inflammation, repair the gut lining, temper immune responses. etc.

The microbe found deficient is f. prausnitzii which is an anaerobe meaning it cannot live in an oxygen environment which means it cannot be given as a supplement. Low levels are also found in IBS, IBD, Crohn's, Colitis and other inflammatory conditions. It appears that it becomes reduced in high oxidative environments - read that high immune activity.

The article that @Consul posted said this:
Conclusions: The diversity of the microbiome in the FMS group was lower than that in the control group, and the reduced stool propionate levels could be associated with the decreased abundance of propionate-producing bacteria.
 
Back